Pharmaceutical-grade lactic acid as described in the current USP-NF, Ph Eur, and BP monographs is a concentrated aqueous equilibrium mixture of free lactic acid, lactoyllactic acid, water, and minor oligomeric esters; it is not an anhydrous single entity with a fixed water-free purity. The pharmacopoeial assay expresses total acid equivalents as C₃H₆O₃ after alkaline hydrolysis, using an equivalence factor of 90.08 mg of C₃H₆O₃ per millilitre of 1 N sodium hydroxide in the USP procedure and 90.1 mg per millilitre of 1 M sodium hydroxide in the Ph Eur procedure. USP-NF allows not less than 85.0% w/w and not more than 92.0% w/w of C₃H₆O₃, while Ph Eur and BP specify 88.0% w/w to 92.0% w/w. The difference between the two assay ranges has direct consequences for global formulation development because a 100.0 g quantity of USP-grade material at the lower limit contains 85.0 g of titratable acid equivalents, whereas a Ph Eur-grade batch at the lower limit contains 88.0 g; if the same nominal percentage is used in a master formula without lot-specific assay correction, the resulting pH and buffer capacity can differ by approximately 3% relative. The free acid in concentrated solution is partially esterified to lactoyllactic acid, and the ester fraction increases with decreasing water activity and rising storage temperature, so the titrimetric assay is intentionally preceded by saponification or is designed to hydrolyse the ester before the final titration. This equilibrium behaviour also means that density, refractive index, or conductivity alone cannot substitute for the compendial assay in release testing; a density meter may provide a rapid in-process concentration estimate, but the release specification remains the titrated acid equivalent value. The Ph Eur monograph describes the article as clear, colourless or slightly yellow, syrupy, and miscible with water and ethanol; the USP monograph similarly includes limits for reducing sugars and for citric, oxalic, tartaric, and phosphoric acids to exclude poorly purified fermentation or synthetic material.

What Limits Assay and Impurity Acceptance Ranges Across USP-NF, Ph Eur, and BP Monographs?

Across the current USP-NF, Ph Eur, and BP monographs, inorganic and organic impurities are controlled through a combination of specific ion tests, colourimetric or titrimetric limit tests, and liquid chromatography in the Ph Eur/BP text. Chloride in the Ph Eur/BP monograph is controlled at not more than 100 ppm, sulfate at not more than 200 ppm, and calcium at not more than 200 ppm; the USP monograph does not set the same individual ion limits but applies heavy metals at not more than 0.001%, equivalent to 10 ppm, and a residue on ignition limit of not more than 0.1%. The Ph Eur/BP monograph also includes a lead limit at not more than 5 ppm in editions where lead is separately controlled, and a liquid chromatographic related substances test to limit acetic acid, formic acid, and unspecified impurities; the assay by titration cannot distinguish these organic acids, so the chromatographic method is required when monograph compliance is claimed. For residual solvents, synthetic material produced through the lactonitrile route may contain methanol and acetaldehyde-derived impurities; the finished pharmaceutical dosage form must comply with ICH Q3C residual solvent limits, with methanol assigned as a Class 2 solvent with a 30 mg/day permitted daily exposure and a 3000 ppm Option 1 concentration limit. Suppliers of pharmaceutical-grade lactic acid typically set internal methanol limits below 50 ppm because the excipient may be used at several percent in a formulation, and the residual solvent contribution must remain below the finished-product limit. The difference between USP-NF and Ph Eur/BP assay ranges should not be interpreted as a difference in purity strategy but as different monograph histories; a supplier can provide a single bulk material that meets both sets of tests only when the assay result is constrained to the overlapping 88.0% w/w to 92.0% w/w window.

Parameter	USP-NF Lactic Acid	Ph Eur/BP Lactic Acid	Method anchor
Assay as C3H6O3	85.0–92.0% w/w	88.0–92.0% w/w	USP <541>; Ph Eur 2.2.20
Chloride	not individually specified in the general monograph	≤100 ppm	Ph Eur 2.4.4
Sulfate	not individually specified	≤200 ppm	Ph Eur 2.4.13
Calcium	not individually specified	≤200 ppm	Ph Eur 2.4.3
Heavy metals	≤10 ppm	≤10 ppm	USP <231> historical; Ph Eur 2.4.8
Reducing sugars	passes compendial limit test	passes compendial limit test	monograph-specific

In bulk pharmaceutical manufacture, lactic acid can be produced by fermentative homolactic fermentation of carbohydrate substrates or by synthetic hydrolysis of lactonitrile; the two routes generate different enantiomeric profiles. Fermentation with Lactobacillus or Bacillus coagulans yields predominantly L-(+)-lactic acid, whereas the synthetic lactonitrile route produces a racemic mixture unless an asymmetric step or enzymatic resolution is introduced. USP and Ph Eur general monographs for Lactic Acid do not consistently require a specific optical rotation when the label does not claim a single enantiomer; when the material is labelled as L-(+)-lactic acid, the formulator should apply additional identification and chiral purity methods, because the ordinary acid-base titration cannot distinguish D- and L-isomers. Specific optical rotation at 589 nm is used as a screening test, and chiral liquid chromatography or enzymatic assay is used to quantify D-isomer content when the final dosage form has a stereochemical specification. The presence of D-lactic acid is relevant in parenteral nutrition and in infant formulations because D-lactate clearance in humans is slower than L-lactate clearance; published clinical data for paediatric D-lactate acidosis have made enantiomeric purity a significant quality attribute in enteral and parenteral products. For general topical and oral solid dose applications, the racemic mixture is often acceptable, but formulators should not assume that a USP or Ph Eur Lactic Acid certificate provides enantiomeric purity unless the certificate includes a specific optical rotation value and a chiral purity result.

Processing-Grade Equivalents and Metal/Residual Solvent Profiles in Bulk 88–92% w/w Material

Because the acid at pH below 2.0 promotes corrosion in carbon steel, pharmaceutical lactic acid bulk storage and transfer require compatibility with stainless steel 316L or glass-lined equipment; carbon steel is not suitable, and chloride present from fermentation can initiate pitting even in stainless grades at elevated temperature. In bulk receiving, a 1000-L stainless steel 316L receiving tank with a bottom recirculation loop and an in-line pH probe is typically used; sampling after recirculation for at least 30 min reduces top-to-bottom assay variation caused by water vapour exchange at the tank headspace. The standard 88–92% w/w material has a density of approximately 1.20–1.22 g/cm³ at 20 °C and a dynamic viscosity in the range of 40–70 mPa·s at 25 °C; viscosity rises rapidly below 15 °C, and transfer lines should be heat-traced if the material is stored in cold warehouses. Fermentation-derived material is typically purified by acidulation of calcium lactate with sulfuric acid followed by filtration to remove gypsum, then esterification to methyl lactate, distillation, and hydrolysis; this sequence reduces calcium, sulfate, and reducing sugar impurities to compendial levels. Synthetic material from lactonitrile requires rigorous removal of methanol, acetaldehyde, and cyanide-related intermediates; residual solvent certificates should include methanol and acetaldehyde data in addition to the ICH Q3C declarations. Ph Eur/BP and USP monographs impose heavy metal limits, but a modern excipient dossier should also provide elemental impurity data under ICH Q3D using USP <232>/<233> or Ph Eur 5.20, because the traditional heavy metals test does not quantify individual elements with sufficient sensitivity for parenteral applications. The formulator should verify that the supplier has evaluated chromium, nickel, molybdenum, and iron if the material has been held in stainless steel equipment; published data for specific batches may be limited, and a risk assessment should be performed rather than relying solely on the monograph test.

In pharmaceutical formulation practice, lactic acid functions primarily as an acidulant, pH adjuster, and component of lactate buffer systems. The pK_a of lactic acid at 25 °C is 3.86; the useful buffer range is therefore approximately 2.8–4.8. A 10% w/w aqueous solution has a pH of approximately 1.8–2.2 at 25 °C when measured per USP <791> or Ph Eur 2.2.3. For pH adjustment from neutral to acidic pH in topical gels, a diluted 10% w/w lactic acid solution is often used to avoid local pH overshoot and precipitation of polymers such as carbomer or xanthan gum; direct addition of concentrated 88–92% w/w acid to polymer dispersions can create low-pH microenvironments that reduce viscosity or cause coagulation before mixing is complete. In oral liquids, lactic acid may be used at low percentages to acidulate a buffered sorbitol or sucrose vehicle; the amount required is calculated from the buffer capacity of the vehicle and the target pH, but the titration curve must be generated experimentally because the presence of weak acid preservatives such as sorbic or benzoic acid shifts the pH response. Sodium lactate 60% w/w solution is used in lactated Ringer's injection and in some electrolyte concentrates; the ratio of lactic acid to sodium lactate is adjusted to provide the desired pH and sodium load. The formulator should not use lactic acid as a sole preservative; its antimicrobial action is pH-dependent and unreliable above pH 4.5, and preservation must be confirmed by compendial antimicrobial effectiveness testing USP <51> or Ph Eur 5.1.3.

When Poly(Lactic-Co-Glycolic Acid) and Implantable Polymer Synthesis Require Low-Metal-Lactide Feedstock

Although pharmaceutical-grade lactic acid is suitable for topical, oral, and some parenteral pH adjustment, it is not automatically equivalent to polymer-grade lactic acid used in poly(lactic acid) or poly(lactic-co-glycolic acid) synthesis because the polymer route requires conversion to lactide and control of water, free acid, and metal catalyst residues at much tighter levels. The polymerization process usually begins with oligomerization of lactic acid under reduced pressure at 130–180 °C, followed by depolymerization in the presence of tin(II) 2-ethylhexanoate at 0.02–0.05 wt% to produce lactide; the catalyst level and the free acid content of the feedstock influence molecular weight and degradation kinetics. Water above 0.05% w/w in the lactide feedstock hydrolyses lactide to lactic acid and reduces ring-opening polymerization efficiency; therefore, polymer producers specify a water limit that is far below the water content of 8–15% w/w present in pharmaceutical-grade lactic acid solution. The compendial assay and impurity tests do not provide tin content, monomeric hydroxy acid ratio, or acid value at the levels needed for sustained-release polymer manufacture; a separate specification aligned with the supplier's technical data package is required. Formulators developing drug-eluting implants should therefore treat the excipient grade as a starting material rather than a direct monomer source; published data for the conversion of compendial lactic acid to polymer-grade lactide in specific reactor trains is limited, and each campaign should include stress testing for residual lactide, tin, and free acid in the final polymer.

Thermal stability of pharmaceutical lactic acid solutions is governed by esterification of free acid to lactoyllactic acid, oligomer formation, and dehydration reactions that become significant above 100 °C and are accelerated by acid catalysis; the reaction mixture at high temperature can generate lactide, acetaldehyde, carbon monoxide, and water as volatile degradation products. In aqueous formulation matrices at ambient temperature, lactic acid is chemically stable over the pH range 2.0–6.0 for at least 24 months when stored in tight containers, but the exact shelf life must be established under ICH Q1A conditions for the specific formulation. Exposure to strong oxidising agents such as hypochlorite or concentrated nitric acid can generate carbon dioxide and acetic acid; contact with amines can form lactate salts or amides if water is removed. Lactic acid chelates divalent metals, and this property can be beneficial in preventing trace metal oxidation in topical formulations, but it also causes incompatibility with calcium-containing emulsifiers and hard water; a 10% w/w dilution in hard water can precipitate calcium lactate at low temperature. Packaging for bulk pharmaceutical lactic acid is typically high-density polyethylene or stainless steel 316L; glass is acceptable if the closure prevents moisture ingress, because water uptake from humid air will reduce the assay and water loss will increase viscosity and ester content. Stability-indicating methods should include titrimetric assay, pH, density, and liquid chromatography for related substances; the titration alone will not detect a shift in oligomer distribution if acid equivalents are preserved, so a viscosity or density check is often added for routine release of bulk stored material.

Compendial Methods That Anchor the Release and In-House Qualification of Lactic Acid Excipient Batches

For in-house qualification of a lactic acid excipient lot, the release testing sequence should be designed around the compendial monographs plus the application-specific attributes for the dosage form. The testing sequence usually includes appearance, infrared identification against a reference standard, titrimetric assay after alkaline hydrolysis, limit tests for chloride, sulfate, calcium, heavy metals, reducing substances, and residual solvents when the supply chain uses a synthetic route. For parenteral development, the lot should also be tested for bacterial endotoxins per USP <85> or Ph Eur 2.6.14, and for particulate matter in the diluted solution if the manufacturing process does not include a validated filtration step. The compendial methods for these tests are summarised below; the table is a compliance checklist for method transfer rather than a replacement for the mandatory current USP-NF, Ph Eur, and BP texts. Method verification should be performed under the site's quality system, and compendial method equivalency should be demonstrated for each new supplier because trace impurities from different fermentation substrates or synthetic routes can affect retention times and detector response.

Test area	USP reference	Ph Eur/BP reference	Typical application
Titrimety after alkaline hydrolysis	USP <541>	Ph Eur 2.2.20	Assay of total acid equivalents
pH	USP <791>	Ph Eur 2.2.3	10% solution pH and formulation pH
Infrared identification	USP <197>	Ph Eur 2.2.24	Identity confirmation
Liquid chromatography	USP <621>	Ph Eur 2.2.29	Related substances and chiral purity
Optical rotation	USP <781>	Ph Eur 2.2.7	Enantiomer screening
Elemental impurities	USP <232>/<233>	Ph Eur 5.20	ICH Q3D risk assessment
Water determination	USP <921>	Ph Eur 2.5.12	Water content and dilution correction
Bacterial endotoxins	USP <85>	Ph Eur 2.6.14	Parenteral formulation release
Residual solvents	USP <467>	Ph Eur 5.4	Methanol, acetaldehyde control

The monograph texts for lactic acid are revised as part of the pharmacopoeial revision cycle; formulators should verify the current edition and the specific supplier certificate against the intended dosage form. A single certificate of analysis stating “USP/EP/BP grade” is not sufficient for a parenteral dossier unless the certificate includes the additional endotoxin, elemental impurity, and residual solvent data required by ICH Q3C and ICH Q3D. Batch-to-batch variability in the ratio of free acid to lactoyllactic acid can influence pH adjustment calculations in weakly buffered systems, so the formulation development report should record the lot assay, water content, density, and titration curve rather than assuming a fixed concentration from the label alone. This approach permits lot substitution across USP and Ph Eur/BP grades without altering the final product pH, buffer capacity, or electrolyte balance.